Overview of Findings

• Twelve additional venture capital, private equity and corporate investing arms with a history of participating in early-stage investments for neuromodulation and medical devices have been provided within the enclosed spreadsheet.
• Notably, all twelve of the identified investors have an established track record of investing in both neuromodulation and medical device startups.
• Meanwhile, the selected investor organizations vary significantly in terms of their investment mandate, from micro venture capital funds that specialize in early-stage healthcare investments to firms that make deals across a broad array of industries and throughout the startup lifecycle.